This study is a prospective, randomized, open label trial to compare the safety and efficacy
of linagliptin (an oral anti diabetic medication) given orally once daily to an insulin
regimen of glargine once daily plus rapid-acting insulin before meals. Both of these
treatment groups will be given corrective doses of rapid-acting insulin analogs (aspart,
lispro or glulisine) before meals if their blood sugars are > 140 mg/dl.
The patients will be monitored for their blood sugars while the hospital.
If patients are agreeable to participate in the discharge part of the study, the
investigators will randomized them to a treatment group based on their admission HbA1c. The
investigators will follow these patients for 3 months with phone calls and clinic visits, and
will monitor their blood sugars. This is to compare the efficacy of linagliptin and our
discharge treatment algorithm in controlling blood sugars as out patients.
Phase:
Phase 4
Details
Lead Sponsor:
Emory University
Collaborators:
Boston Medical Center Rush University University of Denver